Skip to Main Content

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination With Pembrolizumab or Binimetinib in Adult Patients With Advanced Solid Tumors

Conditions

Phase I

Phase I

What is the purpose of this trial?

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

  • Trial with
    Jacobio Pharmaceuticals Co., Ltd
  • Start Date
    06/08/2021
  • End Date
    09/30/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000029875